Aureus Asset Management LLC boosted its stake in shares of Allergan PLC. (NYSE:AGN) by 8.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 58,526 shares of the company’s stock after purchasing an additional 4,355 shares during the quarter. Allergan PLC. makes up 2.4% of Aureus Asset Management LLC’s investment portfolio, making the stock its 17th biggest holding. Aureus Asset Management LLC’s holdings in Allergan PLC. were worth $14,227,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Hudock Capital Group LLC increased its holdings in Allergan PLC. by 0.4% during the 2nd quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock worth $138,000 after purchasing an additional 2 shares during the period. GWM Advisors LLC increased its holdings in Allergan PLC. by 0.4% during the 1st quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock worth $300,000 after purchasing an additional 5 shares during the period. Burns J W & Co. Inc. NY increased its holdings in Allergan PLC. by 0.7% during the 2nd quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock worth $220,000 after purchasing an additional 6 shares during the period. Pacific Center for Financial Services increased its holdings in Allergan PLC. by 1.3% during the 2nd quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after purchasing an additional 7 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC increased its holdings in Allergan PLC. by 0.5% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock worth $405,000 after purchasing an additional 9 shares during the period. Institutional investors own 82.04% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Aureus Asset Management LLC Buys 4,355 Shares of Allergan PLC. (AGN)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/10/09/aureus-asset-management-llc-buys-4355-shares-of-allergan-plc-agn.html.

Shares of Allergan PLC. (NYSE AGN) opened at 206.75 on Monday. The company has a 50 day moving average price of $218.50 and a 200-day moving average price of $233.15. The firm has a market capitalization of $69.12 billion, a PE ratio of 6.30 and a beta of 1.15. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80.

Allergan PLC. (NYSE:AGN) last posted its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business’s revenue was up 8.8% compared to the same quarter last year. During the same period in the prior year, the company earned $3.35 earnings per share. Equities research analysts expect that Allergan PLC. will post $16.21 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were issued a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 1.35%. The ex-dividend date of this dividend was Wednesday, August 16th. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.

Allergan PLC. declared that its board has approved a stock buyback plan on Monday, September 25th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to purchase up to 2.8% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s management believes its shares are undervalued.

Several equities research analysts have weighed in on the company. UBS AG restated an “outperform” rating and set a $275.00 price target on shares of Allergan PLC. in a report on Wednesday, August 9th. BidaskClub downgraded Allergan PLC. from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Barclays PLC restated an “equal weight” rating on shares of Allergan PLC. in a report on Monday, October 2nd. Wells Fargo & Company restated an “outperform” rating and set a $280.00 price target (up previously from $270.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. Finally, Argus restated a “buy” rating and set a $280.00 price target on shares of Allergan PLC. in a report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $271.64.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.